On September 8, 2026 HCW Biologics Inc. (the "Company" or "HCW Biologics") (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel fusion immunotherapeutics to treat autoimmune diseases, cancer, and senescence-associated dysplasia, reported that the Company has entered into an Exclusive Distribution Agreement with Akron Biotech ("Akron"), a leading manufacturer of ancillary materials and a contract development and manufacturing organization for the cell, gene therapy, and regenerative medicine industries, for the commercialization of HCW11-006 for use as a reagent to support a new method of producing highly functional human CAR-T cells for treating cancer, autoimmune disease, and infectious diseases. Akron operates within a highly specialized global network of biomedical institutions, primarily catering to a customer base of advanced therapy developers, biopharmaceutical companies, and research organizations. Akron manufactures and markets cGMP-compliant ancillary materials (such as cytokines, media supplements, and plasmid DNA) necessary for bringing regenerative medicine from preclinical stages to commercialization.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
HCW11-006, a first-in-class multi-cytokine fusion molecule built with our proprietary TRBC platform, enables production of more potent CAR-T-based immunotherapies by generating a CAR-T population that is highly functional and markedly enriched for long-lived T-memory stem cells (Tscm). Utilizing HCW11-006 as part of a manufacturing strategy may be broadly applicable to increase persistence and functionality of CAR-Ts. Functional persistence of CAR-Ts is limited by conventional and costly manufacturing methods utilizing anti-CD3/CD28 (αCD3/28)/IL-2 stimulation, which generates terminally differentiated and shorter-lived CAR-Ts.
Utilizing HCW11-006 as a reagent in the manufacture of CAR-Ts synergizes the effects of IL-7, IL-15 and IL-21 to promote the generation of a CAR-T cell product with a diverse mix of T cell subsets that exhibit a combination of Tscm self-renewal capacity and enhanced T cell effector function. In addition, as a reagent, HCW11-006 stimulates proliferation of CD8+ T cells, particularly those within the Tscm subset. As a result, HCW11-006 was shown to generate CAR-Ts without requiring αCD3/28/IL-2 activation that are highly enriched in long-lived Tscm and display potent activity across distinct disease experimental models, namely, HIV-1 and B-cell leukemia.
In preclinical studies, CAR-Ts manufactured using HCW11-006 were significantly superior compared to CAR-Ts manufactured using standard methods employing αCD3/28/IL-2 reagents for CAR lentiviral transduction and subsequent expansion and persistence of highly active human CAR-Ts. Clinical studies are planned to further confirm these findings. This research suggests that CAR-T cells produced with HCW11-006 may be a more effective and longer-lasting CAR-T cell immunotherapy than conventional CAR-T cells produced using αCD3/28/IL-2.
Dr. Hing C. Wong, the Company’s Founder and Chief Executive Officer, stated, "We are thrilled that our first product, created using our proprietary TRBC platform, has reached the commercialization stage. HCW11-006 is a novel compound that enables a single molecule to deliver synergistic signals from three different immune-stimulatory cytokines. It is versatile and can be used as a novel reagent to potentially replace the current industry-standard method that relies on αCD3/28/IL-2-based approaches. An approach that employs HCW11-006 as a reagent is highly streamlined and may lower the cost of CAR-T manufacturing compared to existing approaches. Equally important, based on experimental models, HCW11-006 has shown improvement in functional activities and persistence of CAR-Ts following adoptive transfer, a goal the industry has been trying to achieve for the last decade."
Dr. Wong continued, "We are pleased to be entering into a partnership with Akron Biotech and their extensive network of customers who include leading research institutions all over the world that will include the use of CAR-T treatments produced using HCW11-006 as a reagent in clinical research and scale-up of commercialization. Recently, research laboratories and companies approached us directly seeking supply of HCW11-006 to support their cell-based research and development for their novel therapies. We decided to seek a partnership with a leading supplier to commercialize HCW11-006 for use as a reagent. We are excited to enter into this Distribution Agreement to commercialize this application of HCW11-006 as a reagent with an established firm that specializes in manufacturing and distribution of cell-based, gene and regenerative therapies."
Article Referenced in Press Release:
Cole et al., "IL-7/IL-15/IL-21 cytokine-fusion scaffold generates highly functional CAR T cells enriched in long-lived T memory stem cells," Science Advances, Vol. 12, No.11, 13 Mar 2026
(Press release, HCW Biologics, SEP 8, 2026, View Source [SID1234670622])